5-(三氟甲基)-2-糠酰氯 | 65865-25-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 中文名称: 5-(三氟甲基)-2-糠酰氯
• 英文名称: 5-(trifluoromethyl)furan-2-carbonyl chloride
• CAS: 65865-25-0
• 化学式: C₆H₂ClF₃O₂
• 分子量: 198.529
• InChiKey: LDUVGYISWYZCTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2932190090

反应信息

• 作为反应物：
  描述：

  5-(三氟甲基)-2-糠酰氯 在 溶剂黄146 、 三乙胺 、 三氟乙酸 、 magnesium chloride 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 3-Ethyl-1-(4-fluoro-3-nitrophenyl)-5-[5-(trifluoromethyl)furan-2-yl]pyrazole
  参考文献：
  名称：

  Inhibition of HIV-1 capsid assembly: Optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold

  摘要：

  A uHTS campaign led to the discovery of a 5-(5-furan-2-ylpyrazol-1-yl)-1H-benzimidazole series that inhibits assembly of HIV-1 capsid. Synthetic manipulations at N1, C2 and C16 positions improved the antiviral potency by a factor of 1000. The X-ray structure of 33 complexed with the capsid N-terminal domain allowed identification of major interactions between the inhibitor and the protein. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.034
• 作为产物：
  描述：

  [5-(三氟甲基)-2-呋喃]甲醇 在 sodium chlorite 、 2-甲基-2-丁烯 、 草酰氯 、 戴斯-马丁氧化剂 、 N,N-二甲基甲酰胺 作用下， 以 aq. phosphate buffer 、 二氯甲烷 、 叔丁醇 为溶剂， 生成 5-(三氟甲基)-2-糠酰氯
  参考文献：
  名称：

  Inhibition of HIV-1 capsid assembly: Optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold

  摘要：

  A uHTS campaign led to the discovery of a 5-(5-furan-2-ylpyrazol-1-yl)-1H-benzimidazole series that inhibits assembly of HIV-1 capsid. Synthetic manipulations at N1, C2 and C16 positions improved the antiviral potency by a factor of 1000. The X-ray structure of 33 complexed with the capsid N-terminal domain allowed identification of major interactions between the inhibitor and the protein. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.034

文献信息

• [EN] LIVER X RECEPTORS (LXR) MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS HÉPATIQUES X (LXR)
  申请人：PHENEX FXR GMBH

  公开号：WO2018188795A1

  公开（公告）日：2018-10-18

  The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXRß) and act preferably as inverse agonists of LXR.

  本发明涉及含有磺胺基、亚砜基或磺胺亚胺基的化合物，这些化合物与肝X受体（LXRα和/或LXRß）结合，并且作为LXR的拮抗剂。
• Potent 2′-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents
  作者：Raymond J. Patch、Benjamin M. Brandt、Davoud Asgari、Nand Baindur、Naresh K. Chadha、Taxiarchis Georgiadis、Wing S. Cheung、Ioanna P. Petrounia、Robert R. Donatelli、Margery A. Chaikin、Mark R. Player

  DOI：10.1016/j.bmcl.2007.09.057

  日期：2007.11

  A series of 2 '-aminoanilides have been identified which exhibit potent and selective inhibitory activity against the cFMS tyrosine kinase. Initial SAR studies within this series are described which examine aroyl and amino group substitutions, as well as the introduction of hydrophilic substituents on the benzene core. Compound 47 inhibits the isolated enzyme (IC50 = 0.027 mu M) and blocks CSF-1-induced proliferation of bone marrow-derived macrophages (IC50 = 0.11 mu M) and as such, serves as a lead candidate for further optimization studies. (C) 2007 Elsevier Ltd. All rights reserved.
• Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response
  作者：Daniel P. Flaherty、Justin R. Miller、Danielle M. Garshott、Michael Hedrick、Palak Gosalia、Yujie Li、Monika Milewski、Eliot Sugarman、Stefan Vasile、Sumeet Salaniwal、Ying Su、Layton H. Smith、Thomas D. Y. Chung、Anthony B. Pinkerton、Jeffrey Aubé、Michael U. Callaghan、Jennifer E. Golden、Andrew M. Fribley、Randal J. Kaufman

  DOI：10.1021/ml5003234

  日期：2014.12.11

  Cellular proteins that fail to fold properly result in inactive or disfunctional proteins that can have toxic functions. The unfolded protein response (UPR) is a two-tiered cellular mechanism initiated by eukaryotic cells that have accumulated misfolded proteins within the endoplasmic reticulum (ER). An adaptive pathway facilitates the clearance of the undesired proteins; however, if overwhelmed, cells trigger apoptosis by upregulating transcription factors such as C/EBP-homologous protein (CHOP). A high throughput screen was performed directed at identifying compounds that selectively upregulate the apoptotic CHOP pathway while avoiding adaptive signaling cascades, resulting in a sulfonamidebenzamide chemotype that was optimized. These efforts produced a potent and selective CHOP inducer (AC(50) = 0.8 mu M; XBP1 > 80 mu M), which was efficacious in both mouse embryonic fibroblast cells and a human oral squamous cell cancer cell line, and demonstrated antiproliferative effects for multiple cancer cell lines in the NCI-60 panel.
• LIVER X RECEPTORS (LXR) MODULATORS
  申请人：Phenex-FXR GmbH

  公开号：EP3609880A1

  公开（公告）日：2020-02-19
• THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：GRIFFIOEN Gerard

  公开号：US20090054410A1

  公开（公告）日：2009-02-26

  This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides various methods for producing such substituted 1,2,4-thiadiazole derivatives.